Passage through the blood-brain barrier of thyrotropin-releasing hormone encapsulated in liposomes

Postmes, Th. J.; Hukkelhoven, M.W.A.C.; Bogaard, A. E. J. M. van den; Halders, Serve; Coenegracht, J.M.

doi:10.1111/j.2042-7158.1980.tb13051.x

Cited by 16 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described by Tiwri and Amuji (2006), liposomes have generally proven successful as a delivery system for transport drugs across the BBB (although their use is hampered by efficiency and several contradictory reports exist: Tokes et al (1980); Schackert et al (1989). Relative to larger delivery systems, liposomes have been reported to reduce the rate of clearance from blood of molecules that include b-galactosidase (Onodera et al 1983), thyrotropin-releasing hormone (Postmes et al 1980), g-amino butyric acid (GABA) (Loeb et al 1982), or phenytoin (Mori et al 1995). In the case of the GABA and phenytoin, the enhanced delivery across the BBB was confirmed with behavioral analysis including a measurable reduction in chemically induced epilepsy.…”

Section: Nanoparticles and Liposomes For Cns Deliverymentioning

confidence: 95%

Targeted nanoparticle-based drug delivery and diagnosis

Emerich

Thanos

2007

Journal of Drug Targeting

203

101

View full text Add to dashboard Cite

Nanotechnology, or systems/device manufacture at sizes generally ranging between 1 and 100 nm, is a multidisciplinary scientific field undergoing explosive development. The genesis of nanotechnology can be traced to advances in medicine, communications, genomics and robotics. One of the greatest values of nanotechnology will be in the development of new and effective medical treatments (i.e. nanomedicine). This review focuses on the potential of nanomedicine as it relates to the development of nanoparticles for enabling and improving the targeted delivery of therapeutic and diagnostic agents. We highlight the use of nanoparticles for specific intra-compartmental analysis using the examples of delivery to malignant cancers, to the central nervous system, and across the gastrointestinal barriers.

show abstract

Section: Nanoparticles and Liposomes For Cns Deliverymentioning

confidence: 95%

Targeted nanoparticle-based drug delivery and diagnosis

Emerich

Thanos

2007

Journal of Drug Targeting

203

101

View full text Add to dashboard Cite

show abstract

“…In another study, it was reported that liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by dibutyrylcAMP/EDTA in rats [41]. Liposome mediated BBB transport of thyrotropin-releasing hormone (TRH) was also reported [34]. In this study, it was shown that following an intravenous injection, the percentage of injected dose of TRH in the brain increased from 0.12% following the injection of free TRH to 0.28-0.44% following the injection of liposome entrapped TRH after 3 hours.…”

Section: Liposomesmentioning

confidence: 96%

A Review of Nanocarrier-Based CNS Delivery Systems

Tiwari¹,

Amiji²

2006

CDD

180

View full text Add to dashboard Cite

Drug delivery to the central nervous system (CNS) is one of the most challenging fields of research and development for pharmaceutical and biotechnology products. A number of hydrophilic therapeutic agents, such as antibiotics, anticancer agents, or newly developed neuropeptides do not cross the blood brain barrier (BBB) after systemic administration. The BBB is formed by the tight junctions at the brain capillary endothelial cells, which strictly control drug transfer from blood to brain. Drug modification, osmotic opening of cerebral capillary endothelium, and alternative routes for administration (e.g., intracerebral delivery) have been successfully used to enhance drug transport to the CNS. The use of nanocarriers, such as liposomes and solid polymeric or lipid nanoparticles may be advantageous over the current strategies. These nanocarriers can not only mask the BBB limiting characteristics of the therapeutic drug molecule, but may also protect the drug from chemical/enzymatic degradation, and additionally provide the opportunity for sustained release characteristics. Reduction of toxicity to peripheral organs can also be achieved with these nanocarriers. This review article discusses the various barriers for drug delivery to the CNS and reviews the current state of nanocarriers for enhancing drug transport into the CNS.

show abstract

“…In this study, it was shown that following an intravenous (i.v.) injection, compared with free thyrotropinreleasing hormone, the percentage of injected dose of thyrotropinreleasing hormone in the brain increased from 0.12% to 0.28-0.44% following the injection of liposome-entrapped TRH after 3 hours (Postmes et al, 1980). Systemically injected liposomes, even SUVs, are cleared by RES.…”

Section: Liposomesmentioning

confidence: 96%

Microspheres for Targeting Delivery of Anticancer Drugs

2013

Microspheres and Microcapsules in Biotechnology

View full text Add to dashboard Cite

Passage through the blood-brain barrier of thyrotropin-releasing hormone encapsulated in liposomes

Cited by 16 publications

References 8 publications

Targeted nanoparticle-based drug delivery and diagnosis

Targeted nanoparticle-based drug delivery and diagnosis

A Review of Nanocarrier-Based CNS Delivery Systems

Microspheres for Targeting Delivery of Anticancer Drugs

Contact Info

Product

Resources

About